Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEMVAC in Metastatic Triple-Negative Breast Cancer
NCT07078604Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of STEMVAC in triple-negative breast cancer (TNBC), sponsored by University of Washington. Started Mar 2026; status: recruiting.
02
Drugs
STEMVAC
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07078604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078604.